TLDR Dupilumab for eczema may cause hair loss.
Dupilumab, a biologic therapy approved for atopic dermatitis (AD), was generally considered safe based on over 1,000 adult patient exposures, with conjunctivitis being the most notable side effect. However, a case was reported where a patient developed alopecia areata (AA) within 5 weeks of starting dupilumab treatment for AD, highlighting a potential adverse effect not previously emphasized.
77 citations,
June 2017 in “Advances in Therapy” New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
26 citations,
January 2019 in “Expert Opinion on Investigational Drugs” New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
1 citations,
March 2024 in “BioDrugs” Biologics for severe asthma have known side effects, but some new risks need more study.
101 citations,
July 2020 in “Dermatologic therapy” COVID-19 can cause skin issues like rashes and "COVID toes," and people with skin conditions should adjust their treatments if they get the virus.
50 citations,
March 2021 in “Journal of investigational allergology & clinical immunology” Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.
30 citations,
May 2016 in “Expert Opinion on Biological Therapy” New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
